{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:50:12Z","timestamp":1793317812344,"version":"4.5.0"},"reference-count":81,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006827","name":"FL DOH James and Ester King Program","doi-asserted-by":"publisher","award":["9JK04"],"award-info":[{"award-number":["9JK04"]}],"id":[{"id":"10.13039\/100006827","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Central Florida Preeminent Postdoctoral Program","award":["9JK04"],"award-info":[{"award-number":["9JK04"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Treatments targeting TIGIT have gained a lot of attention due to strong preclinical and early clinical results, particularly with anti-PD-(L)1 therapeutics. However, this combination has failed to meet progression-free survival endpoints in phase III trials. Most of our understanding of TIGIT comes from studies of T cell function. Yet, this inhibitory receptor is often upregulated to the same, or higher, extent on NK cells in cancers. Studies in murine models have demonstrated that TIGIT inhibits NK cells and promotes exhaustion, with its effects on tumor control also being dependent on NK cells. However, there are limited studies assessing the role of TIGIT on the function of human NK cells (hNK), particularly in lung cancer. Most studies used NK cell lines or tested TIGIT blockade to reactivate exhausted cells obtained from cancer patients. For therapeutic advancement, a better understanding of TIGIT in the context of activated hNK cells is crucial, which is different than exhausted NK cells, and critical in the context of adoptive NK cell therapeutics that may be combined with TIGIT blockade. In this study, the effect of TIGIT blockade on the anti-tumor activities of human ex vivo-expanded NK cells was evaluated in vitro in the context of lung cancer. TIGIT expression was higher on activated and\/or expanded NK cells compared to resting NK cells. More TIGIT+ NK cells expressed major activating receptors and exerted anti-tumor response as compared to TIGIT\u2212 cells, indicating that NK cells with greater anti-tumor function express more TIGIT. However, long-term TIGIT engagement upon exposure to PVR+ tumors downregulated the cytotoxic function of expanded NK cells while the inclusion of TIGIT blockade increased cytotoxicity, restored the effector functions against PVR-positive targets, and upregulated immune inflammation-related gene sets. These combined results indicate that TIGIT blockade can preserve the activation state of NK cells during exposure to PVR+ tumors. These results support the notion that a functional NK cell compartment is critical for anti-tumor response and anti-TIGIT\/adoptive NK cell combinations have the potential to improve outcomes.<\/jats:p>","DOI":"10.3390\/cancers15102712","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T03:22:19Z","timestamp":1683775339000},"page":"2712","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["TIGIT Expression on Activated NK Cells Correlates with Greater Anti-Tumor Activity but Promotes Functional Decline upon Lung Cancer Exposure: Implications for Adoptive Cell Therapy and TIGIT-Targeted Therapies"],"prefix":"10.3390","volume":"15","author":[{"given":"Md Faqrul","family":"Hasan","sequence":"first","affiliation":[{"name":"Burnett School of Biomedical Science, College of Medicine, University of Central Florida, Orlando, FL 32827, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayler J.","family":"Croom-Perez","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Science, College of Medicine, University of Central Florida, Orlando, FL 32827, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah L.","family":"Oyer","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Science, College of Medicine, University of Central Florida, Orlando, FL 32827, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Dieffenthaller","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Science, College of Medicine, University of Central Florida, Orlando, FL 32827, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza D.","family":"Robles-Carrillo","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Science, College of Medicine, University of Central Florida, Orlando, FL 32827, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Eloriaga","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Science, College of Medicine, University of Central Florida, Orlando, FL 32827, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Kumar","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Science, College of Medicine, University of Central Florida, Orlando, FL 32827, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan W.","family":"Andersen","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Science, College of Medicine, University of Central Florida, Orlando, FL 32827, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4109-5539","authenticated-orcid":false,"given":"Alicja J.","family":"Copik","sequence":"additional","affiliation":[{"name":"Burnett School of Biomedical Science, College of Medicine, University of Central Florida, Orlando, FL 32827, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an Emerging Immune Checkpoint","volume":"200","author":"Guillerey","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in Cancer Immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","article-title":"TIGIT: A Key Inhibitor of the Cancer Immunity Cycle","volume":"38","author":"Manieri","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.4049\/jimmunol.172.12.7385","article-title":"KIR2DL5 Can Inhibit Human NK Cell Activation Via Recruitment of Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP-2)","volume":"172","author":"Yusa","year":"2004","journal-title":"J. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e163620","DOI":"10.1172\/JCI163620","article-title":"Blockade of the Immunosuppressive KIR2DL5\/PVR Pathway Elicits Potent Human NK Cell\u2013Mediated Antitumor Immunity","volume":"132","author":"Ren","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Sanchez-Correa, B., Valhondo, I., Hassouneh, F., Lopez-Sejas, N., Pera, A., Bergua, J.M., Arcos, M.J., Ba\u00f1as, H., Casas-Avil\u00e9s, I., and Dur\u00e1n, E. (2019). DNAM-1 and the TIGIT\/PVRIG\/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy. Cancers, 11.","DOI":"10.3390\/cancers11060877"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.4049\/jimmunol.172.7.3994","article-title":"Cutting Edge: CD96 (Tactile) Promotes NK Cell-Target Cell Adhesion by Interacting with the Poliovirus Receptor (CD155)","volume":"172","author":"Fuchs","year":"2004","journal-title":"J. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.3389\/fimmu.2018.01072","article-title":"Coming of Age: CD96 Emerges as Modulator of Immune Responses","volume":"9","author":"Georgiev","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1083\/jcb.200501090","article-title":"Inhibition of cell movement and proliferation by cell\u2013cell contact-induced interaction of Necl-5 with nectin-3","volume":"171","author":"Fujito","year":"2005","journal-title":"J. Cell Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e000266","DOI":"10.1136\/jitc-2019-000266","article-title":"Nectin4 Is a Novel TIGIT Ligand Which Combines Checkpoint Inhibition and Tumor Specificity","volume":"8","author":"Reches","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.3389\/fimmu.2019.02354","article-title":"The Rise of Nk Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy","volume":"10","author":"Sun","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s11912-022-01281-5","article-title":"Clinical Development of Anti-TIGIT Antibodies for Immunotherapy of Cancer","volume":"24","author":"Florou","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e004711","DOI":"10.1136\/jitc-2022-004711","article-title":"TIGIT-CD226-PVR Axis: Advancing Immune Checkpoint Blockade for Cancer Immunotherapy","volume":"10","author":"Chiang","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_14","unstructured":"(2022, August 02). Genentech: Press Releases|Tuesday. Available online: https:\/\/www.gene.com\/media\/press-releases\/14951\/2022-05-10\/genentech-reports-interim-results-for-ph."},{"key":"ref_15","unstructured":"(2023, January 24). Genentech: Press Releases|Tuesday. Available online: https:\/\/www.gene.com\/media\/press-releases\/14947\/2022-03-29\/genentech-provides-update-on-phase-iii-s."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/cdd.2012.141","article-title":"Recruitment of Grb2 and SHIP1 by the ITT-like Motif of TIGIT Suppresses Granule Polarization and Cytotoxicity of NK Cells","volume":"20","author":"Liu","year":"2013","journal-title":"Cell Death Differ."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"17858","DOI":"10.1073\/pnas.0903474106","article-title":"The Interaction of TIGIT with PVR and PVRL2 Inhibits Human NK Cell Cytotoxicity","volume":"106","author":"Stanietsky","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00262-017-2031-x","article-title":"Blockade of CD112R and TIGIT Signaling Sensitizes Human Natural Killer Cell Functions","volume":"66","author":"Xu","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_19","first-page":"1810804","article-title":"Combination Blockade of the IL6R\/STAT-3 Axis with TIGIT and Its Impact on the Functional Activity of NK Cells against Prostate Cancer Cells","volume":"2022","author":"Haramati","year":"2022","journal-title":"J. Immunol. Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Brauneck, F., Seubert, E., Wellbrock, J., Wiesch, J.S.Z., Duan, Y., Magnus, T., Bokemeyer, C., Koch-Nolte, F., Menzel, S., and Fiedler, W. (2021). Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312919"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1158\/1078-0432.CCR-20-0575","article-title":"IL15 Stimulation with TIGIT Blockade Reverses CD155-Mediated NK-Cell Dysfunction in Melanoma","volume":"26","author":"Chauvin","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1843247","DOI":"10.1080\/2162402X.2020.1843247","article-title":"TIGIT Blockade Enhances Functionality of Peritoneal NK Cells with Altered Expression of DNAM-1\/TIGIT\/CD96 Checkpoint Molecules in Ovarian Cancer","volume":"9","author":"Maas","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1348","DOI":"10.1002\/cti2.1348","article-title":"TIGIT Blockade Enhances NK Cell Activity against Autologous HIV-1-infected CD4+ T Cells","volume":"10","author":"Holder","year":"2021","journal-title":"Clin Transl Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/eji.201545480","article-title":"TIGIT Expression Levels on Human NK Cells Correlate with Functional Heterogeneity among Healthy Individuals","volume":"45","author":"Wang","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e001355","DOI":"10.1136\/jitc-2020-001355","article-title":"Analysis of Tumor-Infiltrating NK and T Cells Highlights IL-15 Stimulation and TIGIT Blockade as a Combination Immunotherapy Strategy for Soft Tissue Sarcomas","volume":"8","author":"Judge","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"34810","DOI":"10.18632\/oncotarget.26199","article-title":"Peritoneal NK Cells Are Responsive to IL-15 and Percentages Are Correlated with Outcome in Advanced Ovarian Cancer Patients","volume":"9","author":"Maas","year":"2018","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1002\/hep.32035","article-title":"Involvement of TIGIT in Natural Killer Cell Exhaustion and Immune Escape in Patients and Mouse Model With Liver Echinococcus Multilocularis Infection","volume":"74","author":"Zhang","year":"2021","journal-title":"Hepatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1200\/JCO.2020.38.15_suppl.9503","article-title":"Primary Analysis of a Randomized, Double-Blind, Phase II Study of the Anti-TIGIT Antibody Tiragolumab (Tira) plus Atezolizumab (Atezo) versus Placebo plus Atezo as First-Line (1L) Treatment in Patients with PD-L1-Selected NSCLC (CITYSCAPE)","volume":"38","author":"Johnson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the Checkpoint Receptor TIGIT Prevents NK Cell Exhaustion and Elicits Potent Anti-Tumor Immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","article-title":"The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK Cells and Cancer: You Can Teach Innate Cells New Tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK Cell Platform for Cancer Immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of Natural Killer Cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"679117","DOI":"10.3389\/fimmu.2021.679117","article-title":"Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy","volume":"12","author":"Shaver","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK Cells for Cancer Immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/0008-5472.CAN-05-2429","article-title":"Natural Killer Cells Produce T Cell-Recruiting Chemokines in Response to Antibody-Coated Tumor Cells","volume":"66","author":"Roda","year":"2006","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","article-title":"A Natural Killer\u2013Dendritic Cell Axis Defines Checkpoint Therapy\u2013Responsive Tumor Microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK Cells Stimulate Recruitment of CDC1 into the Tumor Microenvironment Promoting Cancer Immune Control","volume":"172","author":"Bonavita","year":"2018","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1517\/14712598.5.10.1303","article-title":"Natural Killer-Dendritic Cell Cross-Talk in Cancer Immunotherapy","volume":"5","author":"Kalinski","year":"2005","journal-title":"Expert Opin. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.17751","article-title":"Adoptive Immunotherapy with Double-Bright (CD56 Bright \/CD16 Bright ) Expanded Natural Killer Cells in Patients with Relapsed or Refractory Acute Myeloid Leukaemia: A Proof-of-Concept Study","volume":"195","author":"Silla","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"861681","DOI":"10.3389\/fimmu.2022.861681","article-title":"Cryopreserved PM21-Particle-Expanded Natural Killer Cells Maintain Cytotoxicity and Effector Functions in Vitro and in Vivo","volume":"13","author":"Oyer","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Oh, E., Min, B., Li, Y., Lian, C., Hong, J., Park, G.M., Yang, B., Cho, S.Y., Hwang, Y.K., and Yun, C.O. (2019). Cryopreserved Human Natural Killer Cells Exhibit Potent Antitumor Efficacy against Orthotopic Pancreatic Cancer through Efficient Tumor-Homing and Cytolytic Ability. Cancers, 11.","DOI":"10.3390\/cancers11070966"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.4110\/in.2018.18.e31","article-title":"Optimization of Large-Scale Expansion and Cryopreservation of Human Natural Killer Cells for Anti-Tumor Therapy","volume":"18","author":"Min","year":"2018","journal-title":"Immune Netw."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1007\/s00432-016-2247-8","article-title":"Cryopreserved NK Cells in the Treatment of Haematological Malignancies: Preclinical Study","volume":"142","author":"Holubova","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful Adoptive Transfer and in Vivo Expansion of Human Haploidentical NK Cells in Patients with Cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","article-title":"First-in-Human Trial of RhIL-15 and Haploidentical Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia","volume":"3","author":"Cooley","year":"2019","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jcyt.2016.02.006","article-title":"Natural Killer Cells Stimulated with PM21 Particles Expand and Biodistribute in Vivo: Clinical Implications for Cancer Treatment","volume":"18","author":"Oyer","year":"2016","journal-title":"Cytotherapy"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.bbmt.2014.12.037","article-title":"Generation of Highly Cytotoxic Natural Killer Cells for Treatment of Acute Myelogenous Leukemia Using a Feeder-Free, Particle-Based Approach","volume":"21","author":"Oyer","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/imr.12793","article-title":"Cellular Therapy: Adoptive Immunotherapy with Expanded Natural Killer Cells","volume":"290","author":"Lee","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK Cells: A Promising Cellular Immunotherapy for Cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/07357907.2018.1515315","article-title":"Natural Killer Cell-Based Cancer Immunotherapy: A Review on 10 Years Completed Clinical Trials","volume":"36","author":"Suen","year":"2018","journal-title":"Cancer Investig."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2018-01-825240","article-title":"Myeloma Escape after Stem Cell Transplantation Is a Consequence of T-Cell Exhaustion and Is Prevented by Tigit Blockade","volume":"132","author":"Minnie","year":"2018","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/2326-6066.CIR-18-0725","article-title":"Blockade of TIGIT\/CD155 Signaling Reverses t-Cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma","volume":"7","author":"Wu","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT Immune Checkpoint Blockade Restores CD81 T-Cell Immunity against Multiple Myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e1509819","DOI":"10.1080\/2162402X.2018.1509819","article-title":"PD-L1 Blockade Enhances Anti-Tumor Efficacy of NK Cells","volume":"7","author":"Oyer","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2\u2212\u0394\u0394CT Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Croom-Perez, T.J., Robles-Carillo, L.D., Oyer, J.L., Dieffenthaller, T.A., Hasan, M.F., and Copik, A.J. (2022). Kinetic, Imaging Based Assay to Measure NK Cell Cytotoxicity against Adherent Cells. Methods Cell Biol., In Press, Corrected Proof.","DOI":"10.1016\/bs.mcb.2022.07.012"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e002373","DOI":"10.1136\/jitc-2021-002373","article-title":"Original Research: Oncolytic Parainfluenza Virus Combines with NK Cells to Mediate Killing of Infected and Non-Infected Lung Cancer Cells within 3D Spheroids: Role of Type I and Type III Interferon Signaling","volume":"9","author":"Varudkar","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_60","unstructured":"Andrews, S. (2023, May 06). FastQC: A Quality Control Tool for High Throughput Sequence Data. Available online: https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: A Flexible Trimmer for Illumina Sequence Data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/nprot.2016.095","article-title":"Transcript-Level Expression Analysis of RNA-Seq Experiments with HISAT, StringTie and Ballgown","volume":"11","author":"Pertea","year":"2016","journal-title":"Nat. Protoc."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"lqaa078","DOI":"10.1093\/nargab\/lqaa078","article-title":"ComBat-Seq: Batch Effect Adjustment for RNA-Seq Count Data","volume":"2","author":"Zhang","year":"2020","journal-title":"NAR Genom. Bioinform."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"EdgeR: A Bioconductor Package for Differential Expression Analysis of Digital Gene Expression Data","volume":"26","author":"Robinson","year":"2009","journal-title":"Bioinformatics"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13059-016-1028-7","article-title":"Comprehensive Analyses of Tumor Immunity: Implications for Cancer Immunotherapy","volume":"17","author":"Li","year":"2016","journal-title":"Genome Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2.0 for Analysis of Tumor-Infiltrating Immune Cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3389\/fimmu.2017.00760","article-title":"NK Cell Exhaustion","volume":"8","author":"Bi","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T Cell Exhaustion by Multiple Inhibitory Receptors during Chronic Viral Infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1038\/s41467-019-11947-7","article-title":"Heterogeneity of Human Bone Marrow and Blood Natural Killer Cells Defined by Single-Cell Transcriptome","volume":"10","author":"Yang","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_72","unstructured":"(2023, January 26). Search of: TIGIT|Recruiting, Active, Not Recruiting Studies\u2013List Results\u2013ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?term=TIGIT&Search=Apply&recrs=a&recrs=d&age_v=&gndr=&type=&rslt=."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00262-021-02978-5","article-title":"Increased TIGIT Expressing NK Cells with Dysfunctional Phenotype in AML Patients Correlated with Poor Prognosis","volume":"71","author":"Liu","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.3389\/fimmu.2018.02341","article-title":"Expression of the Inhibitory Receptor Tigit Is Up-Regulated Specifically on Nk Cells with Cd226 Activating Receptor from HIV-Infected Individuals","volume":"9","author":"Yin","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_75","first-page":"2408","article-title":"Decreased Expression of TIGIT in NK Cells Correlates Negatively with Disease Activity in Systemic Lupus Erythematosus","volume":"11","author":"Luo","year":"2018","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"66586","DOI":"10.18632\/oncotarget.11953","article-title":"Altered Expression of CD226 and CD96 on Natural Killer Cells in Patients with Pancreatic Cancer","volume":"7","author":"Peng","year":"2016","journal-title":"Oncotarget"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/icb.2011.15","article-title":"Decreased Expression of DNAM-1 on NK Cells from Acute Myeloid Leukemia Patients","volume":"90","author":"Gayoso","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bbmt.2019.01.013","article-title":"Monitoring TIGIT\/DNAM-1 and PVR\/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia","volume":"25","author":"Hattori","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1158\/1535-7163.MCT-20-0464","article-title":"Restoration of T-Cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies","volume":"20","author":"Preillon","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_80","unstructured":"(2023, January 26). ITeos Presents New Data for Anti-TIGIT Antibody, EOS-448\/GSK4428859A, at the AACR Annual Meeting 2022. Available online: https:\/\/finance.yahoo.com\/news\/iteos-presents-data-anti-tigit-170000345.html?guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAJYWXKCTML13lbl3lrecbFrJl37qWFj33vNp1ZmkVPyDSI5gl2Xt84wo-TeYuQ29Mg4xy7jT5dodQxhDxPewTQ_PeUVXK9BFT037hZn-6VYyt4zK-aKdjs0W0mQK358pTnOmxVFRjk0zjGKlNPFMOl_MhPXxTpym56uehz-mpcJD&guccounter=2."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"828319","DOI":"10.3389\/fimmu.2022.828319","article-title":"An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/10\/2712\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:32:44Z","timestamp":1760124764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/10\/2712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":81,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["cancers15102712"],"URL":"https:\/\/doi.org\/10.3390\/cancers15102712","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]}}}